Literature DB >> 10492144

An autopsy case of malignant mesothelioma with osseous and cartilaginous differentiation: bone morphogenetic protein-2 in mesothelial cells and its tumor.

Y Kiyozuka1, H Miyazaki, K Yoshizawa, H Senzaki, D Yamamoto, K Inoue, K Bessho, Y Okubo, K Kusumoto, A Tsubura.   

Abstract

An autopsy case of biphasic malignant mesothelioma with osseous and cartilaginous differentiation diffusely involving the peritoneal cavity was confirmed by light microscopic histochemistry, immunohistochemistry, and electron microscopy. A reverse transcription-polymerase chain reaction using specific primers for bone morphogenetic protein-2 (BMP-2) revealed weak positive transcript in normal mesothelial cells and up-regulated expression around bone-forming malignant mesothelioma tissue. However, BMP-2 protein expression was detected only in the marginal zone of bone trabeculae and spindle-shaped mesothelioma cells distributed around bone trabeculae in tumor tissue. The distribution of type IV collagen in tumor tissue was in accordance with the BMP-2 expression. Normal mesothelial cells and tumor cells expressed BMP-2 mRNA, but the BMP-2 protein expression was restricted to the bone-forming area in the malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10492144     DOI: 10.1023/a:1026627413715

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Primary tumours of the pleura.

Authors:  W T McCAUGHEY
Journal:  J Pathol Bacteriol       Date:  1958-10

2.  Malignant mesotheliomas with osseous and cartilaginous differentiation.

Authors:  S A Yousem; L Hochholzer
Journal:  Arch Pathol Lab Med       Date:  1987-01       Impact factor: 5.534

3.  Bone: formation by autoinduction.

Authors:  M R Urist
Journal:  Science       Date:  1965-11-12       Impact factor: 47.728

4.  Pleural mesothelioma associated with massive hepatic calcification and unusual metastases.

Authors:  V Persaud; E M Bateson; C D Bankay
Journal:  Cancer       Date:  1970-10       Impact factor: 6.860

5.  Growth regulation of human prostate cancer cells by bone morphogenetic protein-2.

Authors:  H Ide; T Yoshida; N Matsumoto; K Aoki; Y Osada; T Sugimura; M Terada
Journal:  Cancer Res       Date:  1997-11-15       Impact factor: 12.701

6.  Bone morphogenetic protein-2 but not bone morphogenetic protein-4 and -6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts, and U2-OS cells.

Authors:  M LInd; E F Eriksen; C Bünger
Journal:  Bone       Date:  1996-01       Impact factor: 4.398

7.  Two malignant pleural mesotheliomas with unusual histological features.

Authors:  B Goldstein
Journal:  Thorax       Date:  1979-06       Impact factor: 9.139

8.  Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression.

Authors:  N S Cunningham; V Paralkar; A H Reddi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

9.  Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma.

Authors:  J Holden; A Churg
Journal:  Am J Surg Pathol       Date:  1984-04       Impact factor: 6.394

10.  Bone morphogenetic protein 4: a ventralizing factor in early Xenopus development.

Authors:  L Dale; G Howes; B M Price; J C Smith
Journal:  Development       Date:  1992-06       Impact factor: 6.868

View more
  11 in total

1.  The effects of α-zearalanol on the proliferation of bone-marrow-derived mesenchymal stem cells and their differentiation into osteoblasts.

Authors:  Shaohui Zong; Gaofeng Zeng; Ye Fang; Jinzhen Peng; Bin Zou; Taihang Gao; Jingmin Zhao
Journal:  J Bone Miner Metab       Date:  2015-05-06       Impact factor: 2.626

Review 2.  The Yin and Yang of bone morphogenetic proteins in cancer.

Authors:  Ashok Singh; Rebecca J Morris
Journal:  Cytokine Growth Factor Rev       Date:  2010-08-04       Impact factor: 7.638

3.  A case of biphasic mesothelioma with osseous and chondromatous differentiation in a cat.

Authors:  Ahmad N Al-Dissi; Helene Philibert
Journal:  Can Vet J       Date:  2011-05       Impact factor: 1.008

Review 4.  A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.

Authors:  Aaron W James; Gregory LaChaud; Jia Shen; Greg Asatrian; Vi Nguyen; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Tissue Eng Part B Rev       Date:  2016-04-19       Impact factor: 6.389

5.  Experimental construction of BMP2 and VEGF gene modified tissue engineering bone in vitro.

Authors:  Jia Jiang; Cun-Yi Fan; Bing-Fang Zeng
Journal:  Int J Mol Sci       Date:  2011-03-07       Impact factor: 5.923

Review 6.  Essentials for Pathological Evaluation of Peritoneal Surface Malignancies and Synoptic Reporting of Cytoreductive Surgery Specimens-A review and evidence-based guide.

Authors:  Aditi Bhatt; Suniti Mishra; Loma Parikh; Sandeep Sheth; Imran Gorur
Journal:  Indian J Surg Oncol       Date:  2019-03-19

7.  The osteogenic study of tissue engineering bone with BMP2 and BMP7 gene-modified rat adipose-derived stem cell.

Authors:  Wang Qing; Chen Guang-Xing; Guo Lin; Yang Liu
Journal:  J Biomed Biotechnol       Date:  2012-06-21

8.  Mesothelial cell differentiation into osteoblast- and adipocyte-like cells.

Authors:  Sally M Lansley; Richelle G Searles; Aina Hoi; Carla Thomas; Helena Moneta; Sarah E Herrick; Philip J Thompson; Mark Newman; Gregory F Sterrett; Cecilia M Prêle; Steven E Mutsaers
Journal:  J Cell Mol Med       Date:  2011-10       Impact factor: 5.310

9.  A Subset of Malignant Mesothelioma Tumors Retain Osteogenic Potential.

Authors:  S M Lansley; B Pedersen; C Robinson; R G Searles; G Sterrett; I van Bruggen; R A Lake; S E Mutsaers; C M Prêle
Journal:  Sci Rep       Date:  2016-11-25       Impact factor: 4.379

10.  Effects of BMP2 and VEGF165 on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells.

Authors:  Zhaowei Lin; Jiang-Sheng Wang; Lijun Lin; Jingwen Zhang; Yunlong Liu; Ming Shuai; Qi Li
Journal:  Exp Ther Med       Date:  2013-12-27       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.